Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: March 22, 2023

Details for Patent: 6,403,567

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 6,403,567 protect, and when does it expire?

Patent 6,403,567 protects LEXISCAN and is included in one NDA.

This patent has twenty-nine patent family members in twenty-three countries.

Summary for Patent: 6,403,567

Title:	N-pyrazole A2A adenosine receptor agonists
Abstract:	2-adenosine N-pyrazole compositions having the following formula: ##STR1## and methods for using the compositions as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
Inventor(s):	Zablocki; Jeff A. (Mountain View, CA), Elzein; Elfatih O. (Freemont, CA), Palle; Venkata P. (Mountain View, CA)
Assignee:	CV Therapeutics, Inc. (Palo Alto, CA)
Application Number:	09/338,185
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,403,567
Patent Claim Types: see list of patent claims	Compound; Composition; Formulation; Use;

Drugs Protected by US Patent 6,403,567

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astellas	LEXISCAN	regadenoson	SOLUTION;INTRAVENOUS	022161-001	Apr 10, 2008	AP	RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing	Y	Y		METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 6,403,567

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	024441	See Plans and Pricing
Austria	256141	See Plans and Pricing
Australia	7132400	See Plans and Pricing
Australia	760806	See Plans and Pricing
Brazil	0011856	See Plans and Pricing
Canada	2377746	See Plans and Pricing
China	1167709	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt

Express Scripts

Dow

Boehringer Ingelheim

McKinsey

Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.